Fig. 2From: AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutationsEffect of combination treatment with AT-101 and gefitinib on cell viability of NSCLC cells with the T790M mutation. Top, cell viability was determined by the MTT assay. Data are shown as mean ± SD of three independent experiments. Bottom, the combined effect of the two drugs was evaluated on the basis of the combination index (CI) of each drug fractionBack to article page